Skip to main content
TipRanks
Go Ultimate75% OFF

Medline (MDLN) Q3 2026 Earnings Report

330 Followers

MDLN Q3 2026 EPS Results

Actual EPS
$0.44
Consensus EPS
$0.34
Beat/Miss
Beat by +$0.10
One Year Ago EPS
$0.31

MDLN Q3 2026 Revenue Results

Actual Revenue
$7.86B
Expected Revenue
$7.72B
Beat/Miss
Beat by +$134.03M
YoY Revenue Growth
―

Earnings Announcement Details

Quarter
Q3 2026
Date
11/04/2026
Time
Before Open
Conference Call
Wednesday, November 4, 2026
MDLN Upcoming Earnings

Medline's next earnings date is estimated for March 3, 2027, based on past reporting schedules.

Q3 2026 Earnings Call Audio

MDLN Q3 2026 Earnings Call
0:00 / 0:00

Q3 2026 Earnings Slide Deck

Q3 2026 Earnings Call Summary

Q3 2026
Earnings Call Date:Nov 04, 2026|% Change Since:8.65%|
Earnings Call Sentiment|Positive

The call was broadly positive, supported by 10% third-quarter sales growth, 12% adjusted EBITDA growth, strong cash generation, improved leverage, raised 2026 organic sales guidance, customer-signing momentum, and continued strategic investment. The main concerns were near-term margin pressure, lower Supply Chain Solutions margins, elevated inflation and freight costs, the financial impact of the Tracy fire, and ongoing quality-related investments and uncertainty. Management nevertheless maintained its long-term growth outlook and described the underlying commercial momentum as strong.

Company Guidance

For 2026, Medline raised full year organic sales guidance to 10% to 10.5% from 9% to 10%, reaffirmed adjusted EBITDA guidance of $3.3 billion to $3.4 billion and expects to land at approximately the midpoint, and expects Middle East conflict costs of $80 million, up from $70 million; Supply Chain Solutions margin is expected to remain in the mid-4s the remainder of this year. For its preliminary 2027 framework, which is subject to change, Medline expects net sales growth in the high single digits and adjusted EBITDA growth in the low to mid single digits, assumes tariff rates remain at current levels through 2027 and diesel, raw materials, and finished good costs remain at current elevated levels, plans a larger than usual price increase early in the first quarter, expects approximately $20 million to $30 million in restructuring costs in the fourth quarter and approximately $80 million to $90 million in annualized savings primarily realized in 2027, and expects adjusted EBITDA growth to return to at or above net sales growth in 2028.

  • Strong Third-Quarter Sales GrowthThird-quarter net sales increased 10% year over year to $7.9 billion, driven almost entirely by organic growth, with minimal foreign-currency impact. Every segment and channel contributed to growth.
  • Medline Brand Growth Across Product CategoriesMedline Brand third-quarter net sales increased 7% to $3.6 billion, with growth across all three product categories.
  • Supply Chain Solutions ExpansionSupply Chain Solutions third-quarter net sales increased 14% to $4.2 billion, driven by new customer implementations and growth within existing customers. The growth expands the opportunity to convert customers to Medline Brand products over time.
  • Surgical Solutions and Lab GrowthSurgical Solutions net sales increased 8% to $1.7 billion, driven by surgical kitting and broader demand for operating-room products. Lab and Diagnostics net sales increased 14% to $272 million, driven by existing-customer growth and new customer implementations.
  • Frontline Care and Channel PerformanceFrontline Care net sales increased 4% to $1.7 billion, driven by demand for exam gloves and personal care. U.S. acute-care sales increased 12% to $5.5 billion, U.S. nonacute-care sales increased 6% to $1.9 billion, and international sales increased 8% to $518 million.
  • Adjusted EBITDA GrowthThird-quarter adjusted EBITDA increased 12% year over year to $1.0 billion, and adjusted EBITDA margin increased 10 basis points to 12.2%. Strong sales growth and tariff refunds drove the increase.
  • Customer Signings on TrackMedline reported another strong quarter of total new customer signings across multiple channels, including physician-office business with one of the largest U.S. health systems and hospital-lab business with a large Midwest nonprofit integrated delivery network. Based on results to date and pipeline strength, management remains confident in reaching its full-year $1 billion customer-signings goal.
  • Canada Prime Vendor RolloutThe first Canadian prime-vendor partnership with Mohawk Medbuy is live at five hospitals, with strong service levels and positive customer feedback. Medline expects to complete the rollout by the end of the first quarter of 2027.
  • Tracy Distribution Center ProgressThe new Tracy, California distribution center is on track to open by year-end following the fire at the previous facility. It will add regional capacity and include Medline's largest single AutoStore installation to date, which is expected to improve throughput and efficiency in mid-2027.
  • Distribution Network Capacity InvestmentsMedline is adding millions of square feet of distribution space through three new facilities with AutoStore automation: a 1.2 million-square-foot center in Dallas-Fort Worth, a 1 million-square-foot center in Southern California, and an 800,000-square-foot facility in Michigan. The company stated that these facilities will improve supply-chain resilience and responsiveness.
  • Strong Cash Flow and Improved LeverageFree cash flow was $1.8 billion for the first nine months of the year. Cash and short-term investments were $3.6 billion, and net leverage improved to 2.5x from 2.9x in the prior quarter. Medline also made a $750 million term-loan prepayment in October.
  • Raised 2026 Organic Sales GuidanceMedline raised full-year 2026 organic sales guidance for the third consecutive quarter to 10% to 10.5% from 9% to 10%. The company reaffirmed adjusted EBITDA guidance of $3.3 billion to $3.4 billion and expects to finish approximately at the midpoint.
  • 2027 Sales Growth FrameworkMedline expects 2027 net sales growth in the high single digits, driven by same-store sales, new customer implementations, and modest pricing. The company also plans to implement a larger-than-usual price increase early in the first quarter to offset a portion of inflationary cost pressures.
  • Medline Brand Conversion OpportunityManagement stated that Medline Brand conversion generates savings for customers and margin-dollar growth for Medline. For new implementations, the company expects approximately 10% brand conversion in the first year and 2% to 4% thereafter, consistent with prior history.
  • Restructuring Savings ProgramMedline launched an enterprise-wide restructuring program to streamline its organizational structure, reduce duplication, and improve productivity. The company expects approximately $20 million to $30 million of restructuring costs in the fourth quarter, excluded from adjusted EBITDA, and approximately $80 million to $90 million of annualized savings primarily realized in 2027.
  • Share Repurchase AuthorizationMedline authorized its first $1 billion share-repurchase program. Management said it will use the authorization opportunistically, including potential open-market purchases and possible purchases from sponsors, while retaining flexibility for business investment, acquisitions, and debt reduction.
  • Continued Strategic Investment and Long-Term Earnings OutlookManagement reiterated that investing in the business remains the top capital-allocation priority, including distribution centers, automation, operations, the sales force, and new-product development. The company continues to expect adjusted EBITDA growth to return to at or above net-sales growth in 2028.
  • Global Quality Action Plan ProgressMedline engaged independent third parties to assess more than 30 manufacturing sites worldwide and is investing in people, processes, and technology while continuing product remediation. Management stated that the quality-plan investments known today are reflected in 2026 guidance and the 2027 framework.
  • Lab and Diagnostics Cross-Selling ModelManagement stated that every relevant customer has an in-hospital or physician-office lab opportunity, with an estimated 30% convertible opportunity. The company said it captures about 10% initially, doubles the opportunity when it signs a new product vendor, and grows 3% to 4% thereafter, while using the existing MedSurg delivery network to limit incremental distribution costs.

MDLN Earnings History

MDLN earnings history
Report DateFiscal QuarterForecast / EPSLast Year's EPSEPS YoY ChangePress Release
Mar 03, 20272026 (Q4)0.39-0.23――
Nov 04, 20262026 (Q3)0.340.440.3141.94% (+0.13)
Aug 05, 20262026 (Q2)0.350.500.4220.19% (+0.08)
May 06, 20262026 (Q1)0.290.330.4-18.11% (-0.07)
Feb 25, 20262025 (Q4)0.240.230.36-37.67% (-0.14)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat Missed